Recently, German researchers have discovered through recombinant human proteins that a drug for the treatment of blood tumors can be used for the treatment of anti-NMDA receptor encephalitis, effective treatment of critically ill patients.
Anti-NMDA receptor encephalitis i.e. anti-N-methyl-D-aspartate receptor encephalitis, is an autoimmune disease. Schizophrenia, epilepsy, movement disorders and other symptoms caused by brain inflammation may lead to death. In recent years, this encephalitis mainly happens in females gained attention by the medical field.
Researchers at the Charité University Hospital in Berlin and at the German Neurodegenerative Disease Research Center in Berlin, Germany found that the standard of care available to critically ill patients with encephalitis was limited and that the addition of the drug bortezomib was based on standard therapy, resulting in the quick improvement of five critically ill patients. Bortezomib is a proteasome inhibitor originally used to treat rare blood tumor-plasmacytomas.
NMDA receptors play an important role in the process of brain signaling. But plasma cells produce antibodies that block the normal functioning of NMDA receptors in patients with NMDA receptor encephalitis. Bortezomib can effectively kill plasma cells so that antibodies can reduce the radical treatment of such encephalitis and bring new treatment options for critically ill patients.
The study was published in the new issue of international academic journal Neurology. By the way, Flarebio offers good-quality recombinant proteins including recombinant ITGB5 for your research.
没有评论:
发表评论